[{"indications": "Indications\u00a0active rheumatoid arthritis;\r\ninflammatory bowel disease, see section 1.5.1 and notes above", "name": "SULFASALAZINE - SULFASALAZINE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "10 Musculoskeletal and joint diseases", "10.1 Drugs used in rheumatic diseases and gout", "10.1.3 Drugs that suppress the rheumatic disease process", "Sulfasalazine", "SULFASALAZINE"], "cautions": "Cautions\u00a0see section 1.5.1 and notes aboveBlood disorders\u00a0Patients should be\r\nadvised to report any unexplained bleeding, bruising, purpura, sore\r\nthroat, fever or malaise. A blood count\r\nshould be performed and the drug stopped immediately if there is suspicion\r\nof a blood dyscrasia.", "side-effects": "Side-effects\u00a0see section 1.5.1 and notes above", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/5309.htm", "doses": ["By mouth, administered on expert advice,\r\nas enteric-coated tablets, initially 500\u00a0mg daily, increased by 500\u00a0mg\r\nat intervals of 1 week to a max. of 2\u20133\u00a0g daily in divided doses"], "pregnancy": "Pregnancy\u00a0section 1.5.1"}, {"indications": "Indications\u00a0treatment of mild to moderate and severe\r\nulcerative colitis and maintenance of remission; active Crohn\u2019s disease;\r\nrheumatoid arthritis (section 10.1.3)", "name": "SULFASALAZINE - AMINOSALICYLATES", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "1 Gastro-intestinal system", "1.5 Chronic bowel disorders", "1.5.1 Aminosalicylates", "SULFASALAZINE"], "cautions": "Cautions\u00a0\n(From 1.5.1 Aminosalicylates: British National Formulary)\nCautions\u00a0Renal function should be monitored before starting an oral aminosalicylate, at 3 months of treatment, and then annually during treatment (more frequently in renal impairment). Blood disorders can occur with aminosalicylates (see recommendation below).; also history of allergy or asthma; G6PD deficiency (%s\n(From 9.1.5 G6PD deficiency: British National Formulary)\n9.1.5 G6PD deficiency); slow acetylator status; risk of haematological and hepatic toxicity (differential white cell, red cell, and platelet counts initially\r\nand at monthly intervals for first 3 months; liver function tests\r\nat monthly intervals for first 3 months); maintain adequate fluid intake; upper gastro-intestinal side-effects common over 4\u00a0g daily; acute porphyria (%s\n(From 9.8.2 Acute porphyrias: British National Formulary)\n9.8.2 Acute porphyrias); interactions: Appendix 1\r\n(aminosalicylates)Blood disorders\u00a0See %s\n(From 1.5.1 Aminosalicylates: British National Formulary)\nBlood disordersPatients receiving aminosalicylates should be advised to report any unexplained bleeding, bruising, purpura, sore throat, fever or malaise that occurs during treatment. A blood count should be performed and the drug stopped immediately if there is suspicion of a blood dyscrasia.", "side-effects": "Side-effects\u00a0see notes above; also cough, insomnia, dizziness,\r\nfever, blood disorders (including Heinz body anaemia, megaloblastic\r\nanaemia), proteinuria, tinnitus, stomatitis, taste disturbances, and\r\npruritus; less commonly dyspnoea, depression, convulsions,\r\nvasculitis, and alopecia; also reported loss of appetite, hypersensitivity\r\nreactions (including exfoliative dermatitis, epidermal necrolysis,\r\nphotosensitivity, anaphylaxis, serum sickness), ataxia, hallucinations,\r\naseptic meningitis, oligospermia, crystalluria, disturbances of smell,\r\nand parotitis; yellow-orange discoloration of skin, urine, and other\r\nbody fluids; some soft contact lenses may be stained", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/2166.htm", "doses": ["By mouth, acute attack 1\u20132\u00a0g 4 times daily\r\n(but see cautions) until remission occurs (if necessary corticosteroids may also be given), reducing to a maintenance\r\ndose of 500\u00a0mg 4 times daily; child 2\u201312 years see BNF for Children", "By rectum, in suppositories, alone or in conjunction\r\nwith oral treatment 0.5\u20131\u00a0g morning and night after a bowel movement; child 5\u201312 years see BNF for Children"], "pregnancy": "Pregnancy\u00a0theoretical risk of neonatal haemolysis in third\r\ntrimester; adequate folate supplements should be given to mother"}, {"indications": "Indications\u00a0active rheumatoid arthritis;\r\ninflammatory bowel disease, see section 1.5.1 and notes above", "name": "SULFASALAZINE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "10 Musculoskeletal and joint diseases", "10.1 Drugs used in rheumatic diseases and gout", "10.1.3 Drugs that suppress the rheumatic disease process", "Sulfasalazine", "SULFASALAZINE"], "cautions": "Cautions\u00a0see section 1.5.1 and notes aboveBlood disorders\u00a0Patients should be\r\nadvised to report any unexplained bleeding, bruising, purpura, sore\r\nthroat, fever or malaise. A blood count\r\nshould be performed and the drug stopped immediately if there is suspicion\r\nof a blood dyscrasia.", "side-effects": "Side-effects\u00a0see section 1.5.1 and notes above", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/5309.htm", "doses": ["By mouth, administered on expert advice,\r\nas enteric-coated tablets, initially 500\u00a0mg daily, increased by 500\u00a0mg\r\nat intervals of 1 week to a max. of 2\u20133\u00a0g daily in divided doses"], "pregnancy": "Pregnancy\u00a0section 1.5.1"}]